Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.

Seizure - 1 Dec 2015

Inoue Kazuyuki, Takahashi Toshiki, Yamamoto Yoshiaki, Suzuki Eri, Takahashi Yukitoshi, Imai Katsumi, Inoue Yushi, Hirai Keita, Tsuji Daiki, Itoh Kunihiko

Abstract excerpt

PURPOSE: Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia. However, the mechanism responsible for this adverse effect is not readily apparent. We previously reported that phenytoin coadministration is a strong risk factor for the development of hyperammonemia during VPA-based therapy. In this study, we focused on glutamine synthetase,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ammonia
Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epilepsy

Share to Glutamate-Ammonia Ligase

Share to Hyperammonemia

Share to Logistic Models

Share to Phenytoin

Share to Valproic Acid

Source

Identifiers

PMID: 26599579
DOI: 10.1016/j.seizure.2015.10.015

Genes

GLUL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.PMID 26599579Read ↗

Association of glutamine synthetase polymorphisms rs2296521, rs10911021 and rs12136955 with plasma ammonia concentration in valproic acid-treated Egyptian epilepsy patients.Semantic proximity Read ↗

Influence of the glutamate-glutamine cycle on valproic acid-associated hepatotoxicity in pediatric patients with epilepsy.Semantic proximity Read ↗

Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.Semantic proximity Read ↗

4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.Semantic proximity Read ↗

Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.Semantic proximity Read ↗

Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.Semantic proximity Read ↗

In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes.Semantic proximity Read ↗

Investigation of novel therapies for hyperammonemiaSemantic proximity Read ↗

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.Semantic proximity Read ↗

A Novel Gain-of-Function GLUL Variant Is Associated With Developmental and Epileptic Encephalopathy With Enlarged Perivascular Spaces.Semantic proximity Read ↗

Glutamate Dehydrogenase as a Promising Target for Hyperinsulinism Hyperammonemia Syndrome Therapy.Semantic proximity Read ↗

Molecular Mechanisms of Glutamine Synthetase Mutations that Lead to Clinically Relevant Pathologies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.